A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
Clinical trial NCT04471727 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04471727
- Sponsor
- Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-14
- Primary completion
- 2028-01-28
- Enrollment
- 232
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.